中企挂牌美国OTC大盘点，848家企业抢占上市先机

Core Insights - By 2025, a total of 848 Chinese companies are expected to be listed on the US OTC market, covering diverse sectors such as renewable energy, biomedicine, and intelligent manufacturing, but showing a stark disparity with "80% concentrated at lower levels, and less than 1% at higher levels" [1] Group 1: Market Overview - The OTC market in the US is undergoing structural changes, with a total of 12,299 listed companies in 2025, a slight decrease of 0.85% from the previous year, but the participation of Chinese companies continues to rise, with a 45% increase in listings compared to 2024, reaching 848 companies, accounting for nearly 20% of the total Asian OTC listings [3] - The OTC market serves as a critical platform for Chinese companies to access cross-border capital, especially in light of new Nasdaq regulations raising entry barriers and the optimization of cross-border financing policies for Chinese firms [3] Group 2: Tier Distribution - The tier distribution of Chinese companies in the OTC market resembles a "pyramid" structure: - Pink Limited (Pink Sheets): 682 companies, accounting for 80.4% of the total, representing the primary tier with the lowest entry requirements [4] - Expert Market: 111 companies, 13.1%, limited to broker-dealer and institutional trading [4] - OTCID (Base Tier): 38 companies, 4.5%, introduced after reforms in July 2025, requiring unaudited financial statements [4] - OTCQB (Growth Tier): 13 companies, 1.5%, requiring audited financials and a minimum of 50 beneficial shareholders [4] - OTCQX (Premium Tier): Only 4 companies, less than 0.5%, meeting the highest compliance standards [4] Group 3: Industry Distribution - The industry distribution of Chinese companies shows a "hard technology-led, multi-dimensional collaboration" characteristic, with renewable energy (28%), biomedicine (22%), and information technology (19%) collectively accounting for 69% of the total, aligning with global trends in OTC listings [5] - Despite a decrease in the total number of companies transitioning to higher tiers from 48 to 35 (a 27.1% year-on-year decline), the transition pathways remain stable, with Nasdaq being the preferred destination for 65.7% of these companies [5] Group 4: Policy Support and Strategic Value - Continuous optimization of cross-border financing policies provides significant support for Chinese companies to list on the OTC market, including streamlined registration processes and reduced approval times for overseas listings [6] - The strategic value of the US OTC market is expected to increase, as Nasdaq plans to tighten its listing requirements, prompting Chinese companies to prepare for OTC listings in advance [6] - For Chinese companies, key strategies for entering the OTC market include accurately matching tiers, strengthening compliance, and leveraging policy benefits to reduce cross-border capital operation costs [6]